/

Società

AA

Non verificato

AAVantgarde

Di cosa scriviamo

Annunci EconomiciBiotecnologiaFinanzaLegge/Diritto/FiscoMedicina Salute Benessere

9 comunicati stampa

Guarda tutti i comunicati

03/11/2025

Biotecnologia

Finanza

AAVantgarde Closes $141 Million Series B Financing to Advance its Clinical Programs in Stargardt Disease and Usher 1B Syndrome

Fonte

Emittente

1.00

0

07/10/2025

Biotecnologia

AAVantgarde announces 3 presentations at ESGCT 2025 annual meeting

Fonte

Emittente

1.00

0

02/10/2025

Biotecnologia

Medicina Salute Benessere

Legge/Diritto/Fisco

Annunci Economici

AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease

Fonte

Emittente

1.00

0

05/09/2025

Biotecnologia

Medicina Salute Benessere

AAVantgarde presents updated positive clinical data from its AAVB-081 program for Usher 1B at EURetina 2025

Fonte

Emittente

1.00

0

28/08/2025

Biotecnologia

Medicina Salute Benessere

AAVantgarde to Present Updated Clinical Data from LUCE-1 Study at EURetina 2025

Fonte

Emittente

1.00

0

12/08/2025

Biotecnologia

Annunci Economici

AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease

Fonte

Emittente

1.00

0

15/07/2025

Biotecnologia

Medicina Salute Benessere

AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial

Fonte

Emittente

1.00

0

12/05/2025

Biotecnologia

AAVantgarde presents positive clinical data from its AAVB-081 program for Usher 1B and preclinical data from its AAVB-039 program for Stargardt at the ARVO 2025 annual meeting

Fonte

Emittente

1.00

0

28/04/2025

Biotecnologia

AAVantgarde appoints Mr. Rasmus Holm-Jorgensen as Chief Financial Officer

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0